6 cycles chemotherapy

DRUG2 trials

Sponsors

Sun Yat-sen University, North Eastern German Society of Gynaecological Oncology

Conditions

Clear Cell CarcinomaFallopian Tube CancerOvarian CancerPrimary Peritoneal CarcinomaRetinoblastoma

Phase 2

A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy

RecruitingNCT05460000

North Eastern German Society of Gynaecological OncologyClear Cell Carcinoma, Fallopian Tube Cancer, Ovarian Cancer +1

Start: 2024-10-11End: 2032-10-01Target: 640Updated: 2026-07-27

Phase 3

Adjuvant Chemotherapy for High-risk Retinoblastoma After Enucleation

Active, not recruitingNCT01906814

Sun Yat-sen UniversityRetinoblastoma

Start: 2013-08-31End: 2024-04-30Updated: 2024-04-09

Related Papers

A randomized, open-label phase II non-inferiority study of niraparib maintenance after 3 versus 6 cycles of platinum-based chemotherapy in patients with completely debulked advanced HRD-positive high-grade ovarian cancer in first-line therapy (N-PLUS/NOGGO-ov53/ENGOT-ov62).

2026-05-15

Three vs 6 Cycles of Chemotherapy for High-Risk Retinoblastoma

JAMA2024-10-2112 citations

First trial of chemotherapy de-escalation in ovarian cancer (OC): A phase III randomized, open label study of niraparib maintenance after carboplatin and paclitaxel in patients with optimally debulked advanced (homologous recombination deficient) HRD high-grade ovarian cancer in first line therapy (N-PLUS/NOGGO-ov53/ENGOT-ov62).

Journal of Clinical Oncology2023-06-011 citations